The Renaissance of Circulating Tumour Cells (CTC) for Translational Research & Clinical Trials
Time: 4:25 pm
day: Day 1 - Track A (2)
Details:
- The Renaissance was a period in Europe, from the 14th to the 17th centuries, marked by a "rebirth of art, culture, and learning”. Today, CTCs are experiencing a “rebirth in clinical research” due to the increased sensitivity of downstream analysis methodologies
- In the era of HER2 targeted therapies including ADCs, detecting HER2 status changes in previously HER2-negative primary breast cancer patients may identify patients who could benefit from HER2-targeted treatments despite their primary tumour's HER2-negative status
- 16–40% of Glioblastoma patients are classified as inoperable and ctDNA is found in less than 10% of glioma patients. CTCs isolated using the Parsortix system can enable genetic, transcriptomic, and proteomic profiling to help classify patients into molecular subgroups for targeted therapies and enrollment into clinical trials
- Longitudinal pan-cancer NGS analysis of CTC-DNA and cfDNA from a single blood sample, demonstrates multi-parametric utility to capture tumour heterogeneity, reveals tumoral evolution, and provides indicators of cancer resistance mechanisms in clinical trials
